Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 26-week, Multi-center, Open-label Study to Investigate the Efficacy and Safety of CDP870 in Active Crohn's Disease Patients, Who Showed Clinical Efficacy in a Remission Induction Study (Study C87037 [NCT00291668]), at Week 26 After Subcutaneous Administration of CDP870 400 mg From Week 8 Until Week 24 at 4-week Intervals

NCT00329550 is registered in ClinicalTrials.gov with UCB Japan Co. Ltd. as lead sponsor.

NCT NCT00329550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00329550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 26-week, Multi-center, Open-label Study to Investigate the Efficacy and Safety of CDP870 in Active Crohn's Disease Patients, Who Showed Clinical Efficacy in a Remission Induction Study (Study C87037 [NCT00291668]), at Week 26 After Subcutaneous Administration of CDP870 400 mg From Week 8 Until Week 24 at 4-week Intervals
Lead sponsor
UCB Japan Co. Ltd.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2006
Completion date
April 30, 2008
Enrollment
40 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease